Clinical Trial Detail

NCT ID NCT02000622
Title Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors AstraZeneca
Indications

breast cancer

Therapies

Olaparib

Vinorelbine

Eribulin

Capecitabine

Age Groups: adult senior

Additional content available in CKB BOOST